10-Q: Drugs Made In America Acquisition Corp. Q3 Update

Drugs Made In America Acquisition Corp. reports net income of $5.7 million for the nine months ended September 30, 2025, driven by trust account interest, but faces going concern doubts.

Summary

• Drugs Made In America Acquisition Corp. (DMAA) is a blank check company incorporated on May 23, 2024, focused on a business combination in the pharmaceutical industry.
• The company completed its Initial Public Offering (IPO) on January 29, 2025, raising $200,000,000 from 20,000,000 units at $10.00 per unit.
• Underwriters exercised their over-allotment option on February 18, 2025, purchasing an additional 3,000,000 units for $30,000,000.
• Simultaneously, the Sponsor purchased 400,000 Private Placement Units for $4,000,000, and an additional 30,000 Private Placement Units for $300,000 with the over-allotment.
• A total of $231,150,000 was placed in a trust account, which had grown to $237,604,232 by September 30, 2025, due to interest earnings.
• For the nine months ended September 30, 2025, the company reported a net income of $5,727,685, primarily from $6,454,232 in interest earned on the trust account.
• General and administrative costs for the nine months ended September 30, 2025, totaled $726,547.
• As of September 30, 2025, the company had cash of $717 and a working capital deficit of $428,415.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to its mandatory liquidation date if a business combination is not completed.
• The deadline to complete a Business Combination is April 29, 2026, with potential extensions up to 21 months if the Sponsor deposits $0.10 per public share for each extension.

Sentiment

Score: 5

Explanation: The filing presents a neutral outlook typical for a SPAC in its pre-combination phase. While it shows positive interest income from the trust account, the inherent risks of a blank check company, the going concern warning, and identified control deficiencies balance the sentiment.

Positives

• Generated significant non-operating income of $6,454,232 from interest on cash and investments held in the Trust Account for the nine months ended September 30, 2025.
• Successfully completed its Initial Public Offering and the over-allotment option, raising substantial capital for a potential business combination.
• The Trust Account balance has grown to $237,604,232 as of September 30, 2025, providing a solid base for a future acquisition.

Negatives

• The company is a blank check company with no operations and does not generate operating revenues.
• Reported a working capital deficit of $428,415 as of September 30, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to the mandatory liquidation date if a business combination is not completed within the Combination Period.
• Disclosure controls and procedures were deemed not effective due to inadequate segregation of duties and insufficient written policies and procedures for accounting, IT, and financial reporting and record keeping.

Risks

• Geopolitical instability from the ongoing Russia-Ukraine and Israel-Hamas conflicts could lead to market disruptions, volatility in commodity prices, credit and capital markets, supply chain interruptions, and increased cyber-attacks, potentially affecting the search for a Business Combination.
• The company's ability to complete a Business Combination successfully is not assured, and failure to do so within the Combination Period will result in liquidation.
• The company is an early-stage and emerging growth company, subject to associated risks.
• Reliance on third-party digital technologies and lack of significant investments in data security protection make the company vulnerable to cybersecurity threats and incidents.
• The company has a working capital deficit and faces substantial doubt about its ability to continue as a going concern if a Business Combination is not completed within the Combination Period.

Future Outlook

The company intends to focus its search for a business combination target in the pharmaceutical industry. It expects to incur significant costs in pursuit of its acquisition plans and does not anticipate generating operating revenues until after the completion of its initial business combination. The company has until April 29, 2026, to complete a business combination, with potential extensions up to 21 months, subject to the Sponsor depositing additional funds into the Trust Account.

Management Comments

• Management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
• Management plans to address the going concern uncertainty through a Business Combination, though there is no assurance of success within the Combination Period.
• Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2025, due to inadequate segregation of duties and insufficient written policies and procedures.

Industry Context

As a Special Purpose Acquisition Company (SPAC), Drugs Made In America Acquisition Corp. operates as a blank check company with the sole purpose of acquiring an existing business. Its stated intention to focus on the pharmaceutical industry aligns with a sector that often requires significant capital for research, development, and market entry, making it a potential target for SPAC mergers. The company's current activities are limited to organizational efforts and identifying a target, typical for a pre-combination SPAC.

Comparison to Industry Standards

• As a blank check company, direct operational comparisons to established pharmaceutical companies are not applicable.
• The company's trust account structure and redemption rights are standard for SPACs, offering public shareholders a pro rata portion of the trust account if a business combination is not completed or if they redeem their shares.
• The identified material weaknesses in disclosure controls and procedures, specifically inadequate segregation of duties and insufficient written policies, are below industry best practices for public companies, regardless of their operational stage.

Corporate Governance

Related Party Transactions

• The Sponsor paid $491,178 in expenses on behalf of the Company, reducing the share subscription receivable to $608,822.
• The company pays the Sponsor or an affiliate $10,000 per month for office space and administrative/support services, totaling $81,000 for the nine months ended September 30, 2025.
• A promissory note from the Sponsor to the Company, which allowed borrowing up to $1,850,000, had $0 outstanding as of September 30, 2025.
• The CFO has a consulting agreement with the company, incurring $22,764 in expenses for the nine months ended September 30, 2025.
• The Sponsor entered into an unsecured subscription promissory note to provide up to $1,100,000 in working capital loans, convertible into Private Placement Units, with $608,822 outstanding as of September 30, 2025.

Stakeholder Impact

• Shareholders: Public shareholders have redemption rights for a pro rata portion of the Trust Account if a Business Combination is not completed or upon approval of a Business Combination. Holders of rights will not receive funds if the company liquidates without a Business Combination.
• Sponsor: The Sponsor has significant financial commitments and risks, including potential liability for claims against the Trust Account and the obligation to deposit funds for extension periods.
• Underwriters: Entitled to a deferred underwriting fee of $6,900,000, payable only upon completion of a Business Combination, and received 230,000 representative shares.

Next Steps

• Identify and evaluate target businesses for a Business Combination, with a focus on the pharmaceutical industry.
• Perform business due diligence on prospective target businesses.
• Structure, negotiate, and complete an initial Business Combination by April 29, 2026, or within an extended period (up to 21 months).
• Address the identified material weaknesses in disclosure controls and procedures, including inadequate segregation of duties and insufficient written policies.

Key Dates

Recommendation

As a blank check company, the stock's value is primarily tied to the cash in the trust account and the potential for a successful business combination. The current filing indicates stable trust account growth from interest, but also highlights the inherent risks of a SPAC, including the going concern warning and control deficiencies. Without a definitive business combination target or significant operational news, the stock is a 'hold' for investors awaiting the outcome of the acquisition process, as its current value largely reflects its liquidation value plus a speculative premium for a future deal.

Keywords

SPAC, blank check company, pharmaceutical industry, business combination, IPO, trust account, 10-Q, financial report, SEC filing, corporate governance, risk factors, going concern